Journal of Nanomaterials

Journal of Nanomaterials / 2015 / Article
Special Issue

Polymer-Based Nano/Composites: Theory, Synthesis, Modifications, and Properties

View this Special Issue

Research Article | Open Access

Volume 2015 |Article ID 340981 |

Christoph S. Nabzdyk, Maggie Chun, Saif G. Pathan, David W. Nelson, Jin-Oh You, Matthew D. Phaneuf, Frank W. LoGerfo, Leena Pradhan-Nabzdyk, "Development of a Composite Electrospun Polyethylene Terephthalate-Polyglycolic Acid Material: Potential Use as a Drug-Eluting Vascular Graft", Journal of Nanomaterials, vol. 2015, Article ID 340981, 7 pages, 2015.

Development of a Composite Electrospun Polyethylene Terephthalate-Polyglycolic Acid Material: Potential Use as a Drug-Eluting Vascular Graft

Academic Editor: Mircea Chipara
Received15 Apr 2015
Revised24 Jul 2015
Accepted03 Aug 2015
Published25 Oct 2015


Intimal hyperplasia (IH), an excessive wound healing response of an injured vessel wall after bypass grafting, typically leads to prosthetic bypass graft failure. In an approach to ameliorate IH, nondegradable poly(ethylene terephthalate) or PET, which has been used in prosthetic vascular grafts for over 60 years, and biodegradable poly(glycolic acid) or PGA were electrospun using different techniques to generate a material that may serve as permanent scaffold and as a drug/biologic delivery device. PET and PGA polymers were electrospun from either a single-blended solution (ePET/ePGA-s) or two separate polymer solutions (ePET/ePGA-d). ePET/ePGA-d material revealed two distinct fibers and was significantly stronger than the single fiber ePET/ePGA-s material. After 21 days of incubation in PBS, ePET-PGA-s showed fiber strand breaks likely due to the degradation of the PGA within the ePET-ePGA-s fiber, while the ePET/ePGA-d material showed intact ePET fibers even after ePGA fiber degradation. The ePET/ePGA- material was able to release red fluorescent dye for at least 14 days. Attachment of human aortic smooth muscle cells (AoSMCs) was similar to both materials. ePET/ePGA-d materials maybe a step towards bypass graft materials that can be custom-designed to promote cellular attachment while serving as a drug delivery platform for IH prevention.

1. Introduction

Prosthetic bypass graft failure is most frequently a result of intimal hyperplasia (IH) at the distal anastomosis [1]. IH is the result of an excessive wound healing response of an injured vessel wall after bypass grafting or angioplasty. Hallmarks of IH are endothelial activation followed by the ad luminal migration of synthetic smooth muscle cells that secrete significant amounts of extracellular matrix. This eventually leads to a hemodynamically relevant luminal narrowing of the conduit. Poly(ethylene terephthalate) or PET has been used for arterial bypass grafts for over 60 years in woven or knitted constructs, both of which require sealants to prevent blood seepage through the graft wall. None of these structural variants have provided a scaffold that mimicked extracellular matrix (ECM), a major component of a blood native vessel onto which cells can grow.

Electrospinning is a versatile technology that can yield nanofiber materials. Interestingly, the materials’ ultrastructure resembles that of ECM [2]. Electrospinning can be used for controlled fiber modification and nanocomposite substrate integration [3, 4]. The materials’ ultrastructure characteristically consists of crisscrossing nano- to micrometer thick fibrils, resembling extracellular matrix. This ultrastructure not only results in a large surface area, which could be utilized for drug delivery, but also allows cellular trafficking. Aside from optimizing prosthetic bypass grafts, researchers have attempted to prevent IH formation via drug release from the prosthetic graft surface [5].

Microarray analysis of developing canine IH lesions identified various target genes that were dysregulated for up to four weeks after bypass graft implantation [6]. RNAi interference may become a promising technology that may help modulate expression of genes contributing to IH and other cardiovascular diseases [79]. As cellular signaling networks are highly redundant, it may be necessary to modulate/silence multiple genes in either a synchronous or metachronous fashion. In a previous study from our group, short-term RNAi release from dip-coated electrospun PET grafts was shown to significantly silence target gene-expression of infiltrating human aortic smooth muscle cells [2]. siRNA dip-coating of ePET did not interfere with cell adhesion, infiltration, or cell viability [2].

The next logical step was to introduce a degradable component into the ePET material using electrospinning technology that could act as reservoir for siRNA or other therapeutic compounds with the goal to prolong siRNA release from within the material. Poly(glycolic acid) or PGA, a biocompatible ester that degrades predictably by ester hydrolysis, appears to be a good candidate biomaterial to provide localized drug delivery. The final construct must meet the following requirements: (1) degradable component has to completely degrade over a predictable period of time, (2) composite material has to retain its backbone structure of robust ePET, (3) introduction of a degradable component should not interfere with cell attachment, and (4) therapeutic compound should be preferentially stored in the degradable component and not in the nondegradable ePET.

The goal of this study is to design and evaluate a composite electrospun material that consists of a nondegradable ePET backbone and interspersed degradable polyglycolic acid (PGA) fibers for biodegradation, simulated drug release, and cell attachment.

2. Methods

2.1. Electrospinning of ePET/ePGA Materials

Electrospinning of ePET, ePGA, single solution ePET/ePGA (ePET/ePGA-s), and dual solution ePET/ePGA (ePET/ePGA-d) was done using a computer-automated electrospinning apparatus. PET (10% w : v) and/or PGA (10% w : v) polymer chips were dissolved in hexafluoroisopropanol (HFIP) and mixed for a minimum of 48 hours on an inversion mixer at 45 rpm. The PET, PGA, PET/PGA-s (blended), and PET/PGA-d (electrospun at the same time from different solutions) were each electrospun using a steady rate of 3 mL solution/hour at +20 kV for 60 minutes. The resulting electrospun materials were collected onto a Teflon-coated mandrel (30 cm diameter). In another set of experiments, DyLight 549 was added to the PGA and PET solutions, respectively, prior to electrospinning. The electrospun materials were dried for 48 hours at 40°C at 99.9% vacuum. All materials were sterilized via ethylene oxide at 25°C for 12 hours under humidified conditions in an Anprolene Sterilizer. Expanded polytetrafluoroethylene (PTFE), one of the more commonly used materials for prosthetic vascular grafts, served as a clinical reference material for the surface morphology and cell culture studies.

2.2. Evaluation of Tensile Strength of ePET, ePGA, ePET/PGA-s, and ePET-PGA-d Materials

Sheets of ePET, ePGA, ePET/ePGA-s, and ePET/ePGA-d were cut into rectangular strips (20 mm × 5 mm; segments/test group/test condition), with thickness measured using an Ames Thickness Gauge. Strength testing was carried out using a -Test Tensile Strength apparatus (MTS Systems, Cary, NC) with a 25 lb load cell and clamps set at a gap distance of 5 mm. The clamp traverse speed was set at a 200 mm/min strain rate until break.

2.3. Degradation and DyLight 549 Release Studies

5 × 5 mm2 segments of ePET, ePET/ePGA-s, and ePET/ePGA-d materials were placed in sterile phosphate buffered saline (PBS) and incubated at 37°C on an orbital shaker for up to 21 days. Samples were rinsed, air-dried, and evaluated using scanning electron microscopy (SEM) or confocal imaging, respectively, using standard techniques.

2.4. Quantification of AoSMC Attachment to PTFE Electrospun Material

Primary human aortic smooth muscle cells (AoSMCs) (Lonza, Walkersville, MD) (passages 4–8) were cultured as described previously [10]. 5 × 5 mm2 segments of each material were cut and placed into 96-well tissue culture plates. AoSMCs (40,000 cells/well) were seeded on top of PTFE, ePET, ePET/ePGA-s, and ePET/ePGA-d materials and allowed to attach. After 3 hours, segments were removed, rinsed, and placed in a new well. alamarBlue® assay was then used to assess cell attachment [2, 10]. AoSMC attachment to the tissue culture well alone served as the positive attachment control and Alamar blue within an empty well served as a negative control.

2.5. Statistical Analysis

One-way analysis of variance (ANOVA) with Bonferroni post hoc correction was applied. A value < 0.05 was considered significant.

3. Results

3.1. Fiber Morphology

While the PTFE graft material consisted of predominantly parallel-aligned fibers with little interfiber space arranged between thick nodes (Figure 1(a)), the ePET material consisted of a fiber mesh with variable interfiber spaces with relatively reduced fiber diameter distribution (Figure 1(b)). ePGA, ePET/ePGA-s, and ePET/PGA-d fibers also showed distinct fiber strand architecture (Figures 1(c)1(f); left panel).

3.2. Polymer Degradation Using SEM

Degradation studies of the ePGA material alone over a 21-day period revealed initial fiber swelling and gradual degradation (Figures 1(c) and 1(d); middle and right panel). Degradation of ePET-PGA-s material resulted in strand breaks between 14 and 21 days (Figure 1(e); middle and right panel) whereas the ePET/ePGA-d material showed that only ePGA fibers degrade over time, leaving an intact ePET fiber network behind (Figure 1(f); middle and right panel) that closely resembles the network of single strand ePET fibers seen in Figure 1(b). ePET/ePGA-d thus has the potential of retaining all of its strength meanwhile allowing more porous architecture for cells to infiltrate and heal the graft as the electrospun PGA component degrades and releases the active siRNA.

3.3. Tensile Strength

ePET materials had significantly more strength (N) as compared to ePET/PGA-d (N) and ePET/PGA-s (N) materials, respectively ( ≤ 0.0001) (Figure 2). Maintaining the ePGA as a separate fiber allowed the ePET/PGA-d material to retain a majority of its strength as compared to ePET/PGA-s, which was significantly weaker. ePGA material alone (N) was the weakest of all of the materials evaluated. We also observed that, compared to ePET/PGA-d, ePET had a slightly higher (19%) strength.

3.4. Identification of ePGA Fiber Location via Using Fluorescent Labeling

A clear separation between fluorescently labeled ePGA and nonlabeled ePET strands can be seen in the ePET/ePGA-d materials indicating no cross-reaction between the two individual polymers (Figure 3(a)). The electrospinning procedure allowed for adjustable fiber ratio within the length of the ePET/ePGA-d polymer (Figure 3(b)).

3.5. DyLight 549 Release from ePGA

Confocal imaging showed that DyLight 549 was released from ePGA of the ePET/PGA-d polymer over 14 days (Figure 4). This DyLight 549 release profile correlated well with the observed degradation rate of the ePGA fibers.

3.6. Cell Attachment

AoSMC attachment to both ePET and ePET/ePGA-d polymers was significantly higher as compared to PTFE (Figure 5). AoSMC attachment to all of the electrospun materials was higher than that of culture plate. The introduction of ePGA fibers in both of the composite polymers did not appear to alter the attachment to the ePET backbone fiber mesh.

4. Discussion

Electrospinning can be used to generate various materials from different polymers [3, 4]. In this study, coelectrospinning resulted in a composite material of a nondegradable and a degradable polymer without polymer cross-reaction. Coelectrospinning of the PET with PGA results in the least reduction of tensile strength as compared to a single solution electrospin. This strength data validates that blending the solutions results in comingling of fibers that may ultimately reduce overall device strength.

More importantly, a compound can be incorporated and released upon ePGA degradation as indicated by DyLight release. The molecular weight of the DyLight molecule is similar to that of bioactive agents such as antiproliferative drugs and siRNA. Even after PGA degradation, there were no strand breaks observed in ePET/ePGA-d materials after 21 days in solution, which is reassuring in regard to the tensile strength of the polymer. Given that ePET/ePGA-d polymer contains a nondegradable and load-bearing component in the form of ePET, mechanical failure of the proposed graft is not a concern, especially when compared to fully degradable bypass grafts [3, 11, 12].

AoSMC attachment was not affected when ePGA was introduced into the composite polymer. This is an important finding, as an ideal graft design should promote initial cell attachment and growth. Further, the electrospinning protocols allowed for fiber density variation within the coelectrospun polymer, which could be used to generate therapeutic compound gradients within the graft.

This data provides first evidence that coelectrospinning of ePET/ePGA may be a viable option for sustained local drug delivery from within a prosthetic arterial bypass graft. This technology will be combined in future experiments with our previously published approach for short-term siRNA release from electrospun PET materials [2]. Additional studies will extensively analyze drug/siRNA loading and delivering capacities, biocompatibility, and tensile strength in vitro and in vivo to evaluate the material’s properties as drug delivering vascular prostheses. Introduction of other polymers such as poly(lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL) with slower degradation rates than PGA may aid in providing sequential and even more sustained drug/siRNA release from the material [3, 11, 12] while possibly adding a stronger polymer to the cospin. These polymer moderations could act synergistically to comprehensively modulate the tissue response to material implantation. This approach may become a platform technology for various biomaterial modifications and applications for implantable surgical devices and possibly arterial bypass grafts.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


This work was supported by NIH 5R01 HL021796-30, NIH 2R01 HL086741-08, T32 HL007734-21, and the William J. von Liebig Foundation funds to Frank W. LoGerfo.


  1. V. S. Sottiurai, J. S. T. Yao, W. R. Flinn, and R. C. Batson, “Intimal hyperplasia and neointima: an ultrastructural analysis of thrombosed grafts in humans,” Surgery, vol. 93, no. 6, pp. 809–817, 1983. View at: Google Scholar
  2. C. S. Nabzdyk, M. C. Chun, H. S. Oliver-Allen et al., “Gene silencing in human aortic smooth muscle cells induced by PEI-siRNA complexes released from dip-coated electrospun poly(ethylene terephthalate) grafts,” Biomaterials, vol. 35, no. 9, pp. 3071–3079, 2014. View at: Publisher Site | Google Scholar
  3. S. Wang, X. M. Mo, B. J. Jiang et al., “Fabrication of small-diameter vascular scaffolds by heparin-bonded P(LLA-CL) composite nanofibers to improve graft patency,” International Journal of Nanomedicine, vol. 8, pp. 2131–2139, 2013. View at: Publisher Site | Google Scholar
  4. J. Han, S. Farah, A. J. Domb, and P. I. Lelkes, “Electrospun rapamycin-eluting polyurethane fibers for vascular grafts,” Pharmaceutical Research, vol. 30, no. 7, pp. 1735–1748, 2013. View at: Publisher Site | Google Scholar
  5. C. Cagiannos, O. R. Abul-Khoudoud, W. DeRijk et al., “Rapamycin-coated expanded polytetrafluoroethylene bypass grafts exhibit decreased anastomotic neointimal hyperplasia in a porcine model,” Journal of Vascular Surgery, vol. 42, no. 5, pp. 980–988, 2005. View at: Publisher Site | Google Scholar
  6. M. Bhasin, Z. Huang, L. Pradhan-Nabzdyk et al., “Temporal network based analysis of cell specific vein graft transcriptome defines key pathways and hub genes in implantation injury,” PLoS ONE, vol. 7, no. 6, Article ID e39123, 2012. View at: Publisher Site | Google Scholar
  7. S. M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl, “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells,” Nature, vol. 411, no. 6836, pp. 494–498, 2001. View at: Publisher Site | Google Scholar
  8. C. S. Nabzdyk, H. Lancero, K. P. Nguyen, S. Salek, and M. S. Conte, “RNA interference-mediated survivin gene knockdown induces growth arrest and reduced migration of vascular smooth muscle cells,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 301, no. 5, pp. H1841–H1849, 2011. View at: Publisher Site | Google Scholar
  9. L. Pradhan-Nabzdyk, C. Huang, F. W. LoGerfo, and C. S. Nabzdyk, “Current siRNA targets in atherosclerosis and aortic aneurysm,” Discovery Medicine, vol. 17, no. 95, pp. 233–246, 2014. View at: Google Scholar
  10. S. Yoshida, C. S. Nabzdyk, L. Pradhan, and F. W. Logerfo, “Thrombospondin-2 gene silencing in human aortic smooth muscle cells improves cell attachment,” Journal of the American College of Surgeons, vol. 213, no. 5, pp. 668–676, 2011. View at: Publisher Site | Google Scholar
  11. S. Chung, N. P. Ingle, G. A. Montero, S. H. Kim, and M. W. King, “Bioresorbable elastomeric vascular tissue engineering scaffolds via melt spinning and electrospinning,” Acta Biomaterialia, vol. 6, no. 6, pp. 1958–1967, 2010. View at: Publisher Site | Google Scholar
  12. M. Chen, S. Gao, M. Dong et al., “Chitosan/siRNA nanoparticles encapsulated in PLGA nanofibers for siRNA delivery,” ACS Nano, vol. 6, no. 6, pp. 4835–4844, 2012. View at: Publisher Site | Google Scholar

Copyright © 2015 Christoph S. Nabzdyk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.